Edwards Lifesciences Corp. unveiled a new option in its heart valve franchise on Tuesday. The Irvine-based valve maker’s Ascendra procedure uses an aortic heart valve replacement system that is less ...

July 23 (Reuters) - Edwards Lifesciences beat analysts' estimates for second-quarter profit and revenue on Thursday, helped by strong demand for its artificial heart valves used in complex cardiac ...

Edwards Lifesciences stock fell Friday, though the medtech company beat Wall Street's top- and bottom-line expectations.

Edwards Lifesciences gains attention after fresh valve data as structural heart devices, valuation debate, and healthcare sentiment remain in focus.

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences said it has secured FDA approval for the first surgical valve replacement designed for patients with ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...

An analyst earlier this month took aim at what’s behind a big run-up in shares of Irvine medical device maker Edwards Lifesciences Corp.: a new type of heart valve that doesn’t require major surgery.